Drug Type Small molecule drug |
Synonyms Tobramycin + CaEDTA, Tobramycin + Calcium EDTA, Tobramycin + Sodium calcium edetate + [3] |
Target |
Action inhibitors |
Mechanism 30S subunit inhibitors(30S ribosomal subunit inhibitors), Chelating agents |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H14CaN2NaO9 |
InChIKeyMUBDSQWHVCAGNW-UHFFFAOYSA-J |
CAS Registry23411-34-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute respiratory infections | Phase 2 | United States | 01 Apr 2024 | |
Acute respiratory infections | Phase 2 | Australia | 01 Apr 2024 | |
Pseudomonas aeruginosa infection | Phase 2 | United States | 01 Apr 2024 | |
Pseudomonas aeruginosa infection | Phase 2 | Australia | 01 Apr 2024 | |
Pulmonary Cystic Fibrosis | Phase 2 | Australia | 01 Apr 2024 | |
Pulmonary Cystic Fibrosis | Phase 2 | United States | 01 Apr 2024 |